U.S. pharmaceutical companies are seeking to lessen their reliance on China-based companies for drug production, ingredients and research, The Wall Street Journal reported Nov. 1. 

All doses of Novo Nordisk's Wegovy and Ozempic are now available in the U.S following a two-year shortage, according to the FDA drug shortage list, which was updated Oct. 30. 

Fort Myers, Fla.-based Lee Health has become the first multisite health system in the U.S. to receive the American Society of Health-System Pharmacists' Certified Center of Excellence designation in Medication Use Safety and Pharmacy Practice. 

Weekly injections of semaglutide, the active ingredient in Ozempic and Wegovy, led to significant reductions in body weight and knee osteoarthritis-related pain, according to a phase 3 study by Novo Nordisk. 

The FDA granted accelerated approval to asciminib for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. 

A modified dosing regimen of donanemab led to a 41% reduction in the risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in early symptomatic Alzheimer's patients, according to a recent study. 

The American Pharmacists Association voiced concern over the rising number of pharmacy closures, saying they threaten access to pharmacists, particularly in rural and underserved communities, according to an Oct. 29 news release from the organization. 

Novant Health Enterprises, a division of Winston-Salem, N.C.-based Novant Health, has debuted a company aimed at enhancing retail, infusion and specialty pharmacy services across the Southeast. 

Becker's asked chief pharmacy officers from hospitals and health systems across the U.S. to share their most beneficial partnerships in 2024.

A recent study revealed a 17.5% increase in asthma-related hospitalizations in the three months following the announcement that GSK would discontinue the widely used asthma medication Flovent, and 24.1% in the following three to six months, ABC News reported Oct.…